Autoimmune Thrombocytopenia
8
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (8)
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.
IASO-782 in Autoimmune Hematological Diseases
Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia
The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.